A phase 2, open label, multi-center, controlled, randomized study of the safety, tolerability and immunogenicity of Novartis meningococcal B recombinant vaccine +/- OMV , when administered to healthy infants at 2,4,6 and /or 12 months of age Herts REC

Trial Profile

A phase 2, open label, multi-center, controlled, randomized study of the safety, tolerability and immunogenicity of Novartis meningococcal B recombinant vaccine +/- OMV , when administered to healthy infants at 2,4,6 and /or 12 months of age Herts REC

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2007

At a glance

  • Drugs Meningococcal vaccine group B (Primary)
  • Indications Meningococcal group B infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 09 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top